Brigatinib INN


Brigatinib: Each film coated tablet contains Brigatinib INN 90 mg.

Brigatinib-180: Each film coated tablet contains Brigatinib INN 180 mg.

Indications: Brigatinib is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)- positive metastatic non-small cell lung cancer (NSCLC).

Dosage and Administration: The recommended dosing regimen for Brigatinib is 90mg orally once daily for the first 7 days; if 90mg is tolerated during the first 7 days, the dose should be increased to 180mg orally once daily. Brigatinib should be administered until disease progression or unacceptable toxicity. If Brigatinib is interrupted for 14 days or longer for reasons other than adverse reactions, resume treatment at 90 mg once daily for 7 days before increasing to the previously tolerated dose. Brigatinib may be taken with or without food. Patients should be instructed to swallow tablets whole. Tablet should not be crushed or chewed. If a dose of Brigatinib is missed or vomiting occurs after taking a dose, an additional dose should be administered and the next dose of Brigatinib should be taken at the scheduled time. Or, as directed by the registered physician.

Use in Pregnancy and Lactation: Brigatinib can cause fetal harm when administered to a pregnant woman. There are no clinical data on the use of Brigatinib in pregnant women. Pregnant women should be advised of the potential risk to a fetus. Lactation: There are no data regarding the secretion of Brigatinib in human milk or its effects on the breastfed infant or milk production. Because of the potential for adverse reactions in breastfed infants, lactating women should not advise to breastfeed during treatment with Brigatinib and for 1 week following the final dose.


Biganib: Each box contains 10 tablets in blister pack.

Biganib-180: Each box contains 7 tablets in blister pack.

Prescribing Description

Related Products

© Copyright Drug International Ltd. 2024 Designed and Developed by ATI Limited.